Enhanced antitumor activity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model

Journal of Neuro-Oncology

Volumn 44, Issue 1, 1999, Pages 7-14

  Chen, Zhong Ping ^a,b   Wang, Gang ^a   Huang, Qiang ^a   Sun, Zhi Fang ^a   Zhou, Li Ying ^a   Wang, An Dong ^a   Panasci, Lawrence C ^b  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Extraneuronal monoamine transporter; Glioma; SarCNU; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CARRIER PROTEIN; MONOAMINE; NALPHA [N (2 CHLOROETHYL) N NITROSOCARBAMOYL]SARCOSINAMIDE;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DIFFUSION; DRUG EFFICACY; FEMALE; GLIOMA; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARMUSTINE; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLIOMA; HUMANS; MALE; MICE; MICE, NUDE; ORGANIC CATION TRANSPORT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032721407     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006245724456     Document Type: Article

References (24)

1. Shapiro WR: Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol 13: 38-45, 1986
2. Lesser GJ, Grossman S: The chemotherapy of high-grade astrocytomas. Semin Oncol 21: 220, 1994
3. Carter KS, Schabel TM Jr, Broler LE, Johnston TP: 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res 16: 273, 1972
4. Walker MD, Green SB, Byar OP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980
5. 2 carrier, which mediates increased cytotoxicity. Cancer Chem Pharmacol 37: 505-508, 1996
6. Panasci LC, Dufour M, Chevalier L, Isabel G, Lazarus P, McQuillan A, Arbit E, Brem S, Feindel W: Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human gliomas compared with BCNU. Cancer Chem Pharmacol 14: 156-159, 1985
7. Skalski V, Rivas J, Panasci LC, Feindel W: The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chem Pharmacol 22: 137-140, 1988
8. 2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity. Biochem Pharmacol 51: 1639, 1996
9. Marcantonio D, Panasci LC, Hollingshead MG, Alley MC, Camalier RF, Sausville EA, Dykes DJ, Carter CA, Malspeis L: SarCNU, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. Cancer Res 57: 3895-3898, 1997
10. Houchens D, Sheridan M, Nines R, Riblet S, Finfrock M, Trigg N: Glioma and medulloblastoma xenografts as models for brain tumor drug development. In: The Sixth International Workshop on Immunodeficient Animals. Basal, Switzerland, pp 157-161, Karger Publishing, 1989
11. Suami T, Kato T, Hisamatsu T: 2-chloroethylnitrosourea congeners of amino acid amides. J Med Chem 25: 829-832, 1982
12. Nöe AJ, Malapetsa A, Panasci LC: Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell line SK-MG-1 is mediated by an epinephrine sensitive carrier system. Mol Pharmacol 44: 204-209, 1993
13. Nöe AJ, Malapetsa A, Panasci LC: Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics. Cancer Res 54: 1491-1496, 1994
14. 11C-labeled BCNU and SarCNU in gliomas studied by PET. J Neuro-Oncol 10: 47-55, 1991
15. Gründemann D, Schechinger B, Rappold GA, Schömig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nature Neuroscience 1: 349-351, 1998
16. Du ZW, Xu GD, Wang Y: Establishment of human glioma cell line (SHG-44) and observation on its characteristics. Chin J Oncol 6: 241-243 (Chi), 1984
17. Huang Q, Du ZW, Xu GD, Liu ZY, Guo YH, Chen GL, Chen, Ma WX, Tan QY, Xu QN, Li B: Establishment of human glioma cell line-nude mice solid tumor model NHG-1 and its characteristics. Chin J Oncol 9: 269-272 (Chi), 1987
18. Tomayko MM, Reynold CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chem Pharmacol 24: 148-154, 1989
19. Chen ZP, McQuillan A, Mohr G, Panasci LC: Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery 42: 1112-1119, 1998
20. Chen ZP, Malapetsa A, Mohr G, Brien S, Panasci LC: Quantitation of ERCC-2 gene expression in human tumor cell lines by reverse transcription-polymerase chain reaction in comparison to Northern blot analysis. Anal Biochem 244: 50-54, 1997
21. Chen ZP, Malapetsa A, Marcantonio D, Mohr G, Brien S, Panasci LC: Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Res 56: 2475-2478, 1996
22. Begleiter A, Lam HYP, Goldenberg GJ: Mechanism of uptake of nitrosourea by L5178Y lymphoblasts in vitro. Cancer Res 37: 1022-1027, 1977
23. Russ H, Staudt K, Martel F, Gliese M, Schömig E: The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. European J Neuroscience 8: 1256-1264, 1996
24. Streich S, Brüss M, Bönisch H: Expression of the extraneuronal monoamine tansporter (uptake2) in human glioma cells. Naunyn-Schmiedeberg's Arch Pharmacol 353: 328-333, 1996